NeuroAiD at ASEAN Neurological Association
Moleac will attend the 12th Biennial Convention of ASEAN Neurological Association (ASNA) & 39th Annual Convention of Philippine Neurological Association (PNA), in Manila, Philippines from 21 to 24 November.
Prof. N Venketasubramanian (Ramani) from Singapore, one of the principal investigators of NeuroAiD’s landmark study, CHIMES-E, will present the following posters:
- Synergistic Effect of Combining MLC601 and Rehabilitation on Post-Stroke Recovery – The CHIMES Study.
- Targeting Stroke Patients with a Higher Potential of Long-term Benefit from Treatment: Insights from the CHIMES-E Study.
- Comparison of Long-term Spontaneous Functional Recovery and Response to Treatment with MLC601 between Cortical and Non-cortical strokes – The CHIMES-E Study.
In addition, Moleac and E*Chimes (distributor of NeuroAiD in the Philippines) will host a Twilight symposium with renowned speaker Prof. Simeon Marasigan from the Philippines to introduce the NEURITES study on 22nd November, 17:00 – 19:00:
- NEURoaid II (MLC901) Assessment in Cognitivitely Impaired Not Demented Subjects: A Pilot Double Blind, Placebo Controlled Randomized Trial in Efficacy and Safety (NEURITES) Study (Preliminary Report).
NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. NeuroAiD properties have been studied extensively in post stroke recovery and the research is widely published. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.
Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.